



US 20210324429A1

(19) **United States**

(12) **Patent Application Publication**
PORRO et al.

(10) **Pub. No.: US 2021/0324429 A1**

(43) **Pub. Date: Oct. 21, 2021**

(54) **PROCESS FOR CELLULAR BIOSYNTHESIS OF POLY D-LACTIC ACID AND POLY L-LACTIC ACID**

(30) **Foreign Application Priority Data**

Aug. 3, 2018 (IT) 102018000007846

(71) Applicants: **UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA, MILANO (IT); GALATEA BIOTECH S.R.L., MILANO (IT)**

Publication Classification

(51) **Int. Cl.**
C12P 7/62 (2006.01)
C12N 9/04 (2006.01)
C12N 9/10 (2006.01)

(72) Inventors: **Daniilo PORRO, CERNUSCO SUL NAVIGLIO (MI) (IT); Paola BRANDUARDI, MILANO (IT); Stefano BERTACCHI, MILANO (IT); Nadia Maria BERTERAME, MILANO (IT)**

(52) **U.S. Cl.**
CPC *C12P 7/625* (2013.01); *C12N 9/0006* (2013.01); *C12Y 208/03001* (2013.01); *C12Y 101/01027* (2013.01); *C12N 9/1029* (2013.01)

(57) **ABSTRACT**

Disclosed is the production by fermentation of poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). In particular, there is provided engineered (prokaryotic or eukaryotic) cells for the direct synthesis of PLLA polymers and engineered eukaryotic cells for the direct synthesis of PDLA polymers starting from a carbon source, including residual biomasses of the different production chains.

(21) Appl. No.: **17/265,135**


(22) PCT Filed: **Jul. 31, 2019**

(86) PCT No.: **PCT/EP2019/070665**

§ 371 (c)(1),

(2) Date: **Feb. 1, 2021**

Specification includes a Sequence Listing.






Figure 1




Figure 2



Figure 3




Figure 4




Figure 5




Figure 6






Figure 7



#	Lib	Mat...	R Match	Prob.	Name
1	M	871	948	97.0	Propanoic acid, 2-hydroxy- methyl ester
2	R	663	739	0.97	3-Ethoxy-1,2-propanediol
3	R	650	712	0.62	Acetic acid, hydroxy-ethyl ester
4	M	637	646	0.40	1,3-Diethoxy-2-propanol
5	M	620	696	0.22	1,2-Dideoxy-1-erythro-pentitol
6	M	609	628	0.15	2-Propanol, 1-ethoxy-
7	M	600	790	0.11	α-(Methylthio)acetamide
8	M	581	664	0.05	2-Nitro-tertiary butanol
9	M	581	617	0.05	2-Propanol, 1-chloro-3-ethoxy-
10	R		581	0.05	Butane, 1-(methylthio)-

Figure 8







Figure 9



#	Lib.	Mat...	R.Match	Prob.	Name
1	R	7.66	8.52	85.6	Propanoic acid, 2-hydroxy-, methyl ester
2	R	6.47	7.39	4.62	3-Ethoxy-1,2-propanediol
3	M	6.43	7.24	3.90	1,2-Dideoxy-1-erythro-pentitol
4	M	6.24	6.72	1.89	2-Propanol, 1-ethoxy-
5	M	6.05	7.49	0.92	1,2-Butanediol, (±)-
6	M	5.82	6.94	0.33	2-Nitro-tertiary butanol
7	R	5.76	6.22	0.26	1,2-Butanediol
8	M	5.74	5.92	0.24	Butyronitrile, 4-ethoxy-3-hydroxy-
9	M	5.74	5.89	0.24	2,3-Butanedithiol
10	M	5.65	6.07	0.17	Hexane, 1-(1-methoxyethoxy)-

Figure 10




Figure 11





Figure 12

**PROCESS FOR CELLULAR BIOSYNTHESIS
OF POLY D-LACTIC ACID AND POLY
L-LACTIC ACID**

CROSS-REFERENCE TO RELATED
APPLICATIONS

[0001] This application is the U.S. national phase of International Application No. PCT/EP2019/070665 filed Jul. 31, 2019 which designated the U.S. and claims priority to IT 102018000007846 filed Aug. 3, 2018, the entire contents of each of which are hereby incorporated by reference.

REFERENCE TO SEQUENCE LISTING
SUBMITTED ELECTRONICALLY

[0002] The content of the electronically submitted sequence listing (Name: 7526-79_SEQ_LISTING.txt; Size: 9.83 kilobytes; and Date of Creation: Feb. 1, 2021) filed with the application is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

[0003] The present invention relates to a process for the production by direct fermentation of poly L-lactic acid (PLLA) from a carbon source by engineered prokaryotic or eukaryotic cells or of poly D-lactic acid (PDLA) from sugars by engineered eukaryotic cells. The invention also refers to cells having a metabolic flow redirected for the synthesis of enantiomerically pure polymers such as PDLA or PLLA starting from a carbon source, which preferably derives from residual biomasses of production chains.

Description of the Related Art

[0004] Polylactic acid (PLA) is a biodegradable biopolymer derived from lactic acid. Due to its chemical-physical properties, it is an unbranched aliphatic polyester, belonging to the class of thermoplastic polymers. Because of its characteristics, PLA is very similar to polyethylene terephthalate (PET), a common plastic used mainly for food packaging. PET has a petrochemical derivation, while PLA is obtained from the polymerization of lactic acid, obtained in turn by fermentation (Jamshidian et al., 2010; Tsuji et al., 2011). The need to avoid processes based on the use of oil, a fossil resource that is depleting due to rapid human consumption, in favor of bio-based systems, is driving several companies to use bioplastics.

[0005] There are several applications of PLA in many sectors, such as: the food sector (packaging, plates, cutlery, glasses, bottles, among others), 3D printing, where it can replace acrylonitrile butadiene styrene (ABS), and the medical field (e.g. biocompatible suture threads, capsules for drug delivery, among others) (Garlotta, 2001; Rasal et al., 2010; Xiao et al., 2012). The versatility of the PLA allows the printing of finished products both in extrusion and in injection, and, remarkably, it is possible to use the machineries and infrastructures already developed for PET (Jamshidian et al., 2010).

[0006] PLA can be stained by masterbatch and mixed with other plastics (biodegradable or not, of petrochemical derivation or not), in order to obtain compounds with new properties. In addition, it is possible to find the PLA in co-polymer form, in which lactic acid monomers alternate

with other hydroxy acids such as 3-hydroxybutyrate (3HB) or glycolate (Choi et al., 2016; Xiao et al., 2012; Tsuji et al., 2010).

[0007] PLA, differently from traditional plastics like PET, is biodegradable in the environment and biocompostable, namely disposable among organic waste. Therefore, a PLA object-product, once its life cycle has ended, is reabsorbed by the soil, favoring the formation of new biomass that can be further used for the production of PLA (Tsuji et al., 2011; Chen and Patel, 2012). As a consequence, the PLA has a circular supply chain thanks to both its origin from renewable biomasses and its intrinsic biodegradability.

[0008] The global PLA market (about 210 thousand tons/year in 2017) is growing steadily and production is expected to increase by 50% by 2022 compared to that recorded in 2017 (www.european-bioplastics.org/market/). There are three types of PLA depending on the enantiomeric forms of the constituent monomers: PLLA composed of only L-lactic acid monomers, the PDLA consisting of only D-lactic acid monomers, and PDLLA consisting of a mixture of both monomers (Jamshidian et al., 2010; Tsuji et al., 2011). PDLA and PLLA are in a semi-crystalline form, while PDLLA in amorphous form (Tsuji et al., 2011). The chirality of the monomers constituting the PLA is transferred to the polymer itself (hence PDLA or PLLA), which acquires precise chirality. This leads, in the solid form, in a different interaction between adjacent first chains and in a possible lamellar or crystalline structure peculiar to the two single enantiomers, which can preserve, at least partially, chirality. In particular, even in the form of a thin film, PDLA or PLLA can present morphology and at least partial chirality of surfaces, peculiar to the specific enantiomer (Maillard and Prud'homme, 2010), showing phenomena of circular dichroism.

[0009] However, considering the chemical-physical characteristics, these polymers are very similar to each other, for example they are soluble in the same organic solvents (e.g. benzene, chloroform, acetonitrile, etc.). Furthermore, there are no significant differences in terms of melting temperature ($T_m \sim 180^\circ \text{C}$.), decomposition temperature ($\sim 200^\circ \text{C}$.), and elongation (20-30%) (Xiao et al., 2012), which mainly depend on the molecular weight of the polymer. From a commercial point of view, the market is dominated by PLLA, which is mainly used for the production of disposable objects. The PDLA has instead a more niche market and applications in the medical field, since, for instance, it may have two beneficial effects for wound healing: (i) providing a protective barrier as a hydrogel; and (ii) serving as an analgesic by sequestering lactate (Goldberg, 2014).

[0010] Traditionally, PLA (in its enantiomerically pure and non-pure forms) is produced by a chemical synthesis, starting from the lactic acid obtained by fermentation. Unlike other bioplastics, such as polyhydroxyalkanoates (PHA), no known natural organisms are able to directly synthesize PLA (Chen and Patel, 2012). The industrial production of PLA occurs mainly through a ring-opening polymerization, by means of a cyclic intermediate, called lactide, capable of facilitating the reaction. However, this chemical process has aspects that reduce the environmental sustainability of this bioplastic: (i) to complete the polymerization it is necessary to use stannic octanoate as a catalyst and (ii) to allow chemical polymerization it is necessary that lactic acid is in its protonated form, and not in the form of lactate (Garlotta, 2001; Jamshidian et al., 2010; Rasal et al.,

2010; Tsuji et al., 2011). However, since the main supply chains of PLA involve the use of lactic acid bacteria, it becomes necessary to treat the final fermentation product with high amounts of acid. In fact, to allow the growth of these organisms it is necessary to maintain constant the pH of the culture broth around a value of 5 (Okano et al., 2010). Since the pK_a of lactic acid is 3.86, under these conditions, the final product is lactate. Consequently, acidification at the end of the fermentation is necessary, as previously mentioned. Moreover, the nutritional needs of lactobacilli are in most cases complex: this determines the need for rich media formulations which are rarely compatible with the use of residual biomasses as a growth substrate. Even more important, this often determines a greater complexity in downstream purification of the desired monomer (Okano et al., 2010). Finally, the lactobacilli, unlike yeasts, are subject to attack by bacteriophages during the fermentation process (Marcó et al., 2012). The use of yeasts is a valid alternative, since many species belonging to this group, for instance the baker's yeast *Saccharomyces cerevisiae*, are able to grow in soils characterized by low pH values, even lower than a value of 3. Yeasts are unicellular microorganisms widely used by the bioindustry. In particular, *S. cerevisiae* is the eukaryotic microorganism best known at the molecular, genetic and biochemical level and has the status of GRAS (Generally Recognized As Safe) microorganism (Porro et al., 2011; Li and Borodina, 2015). Furthermore, compared to bacteria such as lactobacilli, yeasts have less complex nutritional requirements that allow their growth on residual biomasses as reported, as a simple sake of example, by Soares et al., (2017), Jansen et al., (2017) and Choi et al., (2002).

[0011] Although lactic acid fermentation already represents a sustainable step forward for the production of bioplastics compared to the oil-based production, aiming to further reduce the impact of the conventional process based on chemical polymerization, the direct microbiological synthesis represents an ideal solution. As previously mentioned, in nature no known organisms are able to accumulate poly(lactic acid). Instead, unlike eukaryotes, many prokaryotes are however able to produce aliphatic polyesters as reserve polymers. Therefore, the development and use of eukaryotic cells for the production of poly(lactic acid) require a deep and new engineering.

SUMMARY OF THE INVENTION

[0012] The present invention relates to a method for the complete—one-step-biological synthesis of PDLA and/or PLLA, and eukaryotic cells engineered for this purpose. Both biosyntheses include the bioconversion of a carbon source in PDLA and/or PLLA. The metabolic pathways of this invention include the bioconversion of pyruvate to lactate, followed by its activation with a CoA donor, preferably acetyl-CoA, to lactyl-CoA and subsequent polymerization to PDLA and/or PLLA.

[0013] Examples of eukaryotic cells capable of producing PDLA have been already described by Dusseaux et al. (WO2017/108577). However, this approach is quite complex. Indeed, this approach requires the addition of lactic acid to the medium for the production of PDLA and the development of a two phase process. Therefore, lactic acid must be produced by a different cell factory and/or by chemical synthesis. In this respect, lactic acid should be considered as a mandatory substrate and not like an inter-

mediate product (which is the case for the invention here disclosed, see below). Being a substrate, the ability to consume lactic acid as carbon source need to be attenuated or eliminated. Furthermore, this approach also requires methods to increase the productivity of intracellular Coenzyme A (CoA) donor. This goal can be obtained by facilitating the accumulation of intracellular CoA donor and/or by disrupting the pathway(s) using CoA.

[0014] Surprisingly, despite the wider industrial application of PLLA and the many research skills related to the production of PDLA, no examples of prokaryotic or eukaryotic cells capable of producing PLLA have never been described.

[0015] In order to verify the insertion of a metabolic pathway that allows the conversion of carbon source, preferably glucose, into PDLA and/or PLLA, different experiments were performed using engineered yeast strains showing the production of these polymers (see Examples 8-10). FIG. 5 shows a detailed scheme of the synthetic pathway of PDLA and/or PLLA starting from glucose, transformed in yeast cells by the inventors of the present invention.

[0016] In literature there are examples of genetic modifications of the bacterium *Escherichia coli*, in order to directly produce pure PDLA or in the form of co-polymer with 3-HB or other monomers (Cho et al., WO2006/126796; Jung et al., 2010; Yang et al., 2010; Choi et al., 2016). However, the use of *E. coli* has two main limitations: (i) during the fermentation process, the aforementioned microorganism may be subject to attack by bacteriophages, unlike eukaryotic cells (Marcó et al., 2012) and (ii) the metabolism of *E. coli* is characterized by a mixed acid fermentation in which lactic acid is not the sole fermentation product, with consequent effects on the production yield of the metabolite of interest (Castaño-Cerezo et al., 2009). Remarkably, these examples refer to the incorporation of lactic acid only in the enantiomeric form D, while there are no examples of direct PLLA synthesis, or incorporation of L-lactic acid monomers within the biopolymers produced. This is related to the fact that the system based on *E. coli* exploits the natural ability of the bacterium to produce only lactic acid in the enantiomeric form D. Conversely, the cell factories developed by the current invention can produce D-lactic and/or L-lactic acid, allowing the synthesis of PDLA and/or PLLA in both eukaryotic and prokaryotic cells.

[0017] The subject of the present invention is therefore a method of producing PLLA or PDLA in a cell characterized by a carbon flux directed towards the synthesis of PDLA and/or PLLA.

[0018] PDLA synthesis includes the following steps:

[0019] i) conversion of pyruvate to D-lactate in an eukaryotic engineered cell

[0020] ii) synthesis of D-lactyl-CoA by thioesterification of D-lactate with a CoA donor, preferably acetyl-CoA;

[0021] iii) polymerization of D-lactyl-CoA molecules to PDLA.

[0022] PLLA synthesis includes the following steps:

[0023] i) conversion of pyruvate to L-lactate in a prokaryotic or an eukaryotic engineered cell.

[0024] ii) synthesis of L-lactyl-CoA by thioesterification of L-lactate with a CoA donor, preferably acetyl-CoA;

[0025] iii) polymerization of L-lactyl-CoA molecules to PLLA.

[0026] The cells express genes encoding for enzymes aimed at directing the carbon flux towards the synthesis of PDLA and/or PLLA.

[0027] In a preferred embodiment, the aforementioned cell is a eukaryotic cell, preferably a yeast cell, more preferably a *Saccharomyces* cell and even more preferably a *Saccharomyces cerevisiae* cell.

[0028] The yeasts are by way of example described in "The Yeasts" by N. J. W. Kreger-van Rij, 1987. In particular, the genus of yeast can be *Saccharomyces*, *Zygosaccharomyces*, *Candida*, *Hansenula*, *Kluyveromyces*, *Debaromyces*, *Nadsonia*, *Lipomyces*, *Torulopsis*, *Kloeckera*, *Pichia*, *Schizosaccharomyces*, *Trigonopsis*, *Brettanomyces*, *Cryptococcus*, *Trichosporon*, *Aureobasidium*, *Lipomyces*, *Phaffia*, *Rhodotorula*, *Yarrowia*, or *Schwanniomyces*, among others. Preferably, the yeast is selected from the genus *Saccharomyces*, and preferably is *Saccharomyces cerevisiae*. Preferably, the strains of *S. cerevisiae* are BY4742 (EuroScar Accession No. Y10000), CEN.PK 102-5B (MATa, ura3-52, his3-11, leu2-3/112, TRP1, MAL2-8c, SUC2) and 113-11C (MATa, ura3-52, his3-11, TRP1, MAL2-8c, SUC2—Dr. P. Kötter, Institute of Microbiology, Johann Wolfgang Goethe-University, Frankfurt, Germany) or further from industrial strains such as AP, BL, SAU (Arome Plus, Blanche, Sauvignone available from AEB group, Italy) e VIN13 (available from Anchor, France). Yeast strains can be haploid or diploid.

[0029] The coordinated and appropriately regulated expression of the genes coding for the enzymes involved in the new metabolic pathway, introduced by the inventors of the present invention, can be achieved by using a strong and constitutive endogenous promoter, or by introducing more copies of the exogenous genes, or by means of the conversion of the nucleotide sequence with an optimized nucleotide variant in the codons. These are anyhow routine techniques under the competences of the experts in the field.

[0030] In one embodiment of the invention, the eukaryotic cell is able to produce PDLA by expressing exogenous genes, introduced therein, encoding the enzymes involved in polymer synthesis. In a preferred embodiment, the enzymes involved in the aforementioned PDLA production are: i) the enzyme D-lactate dehydrogenase (EC 1.1.1.28), ii) the enzyme propionyl-CoA transferase (EC 2.8.3.1), iii) the enzyme polyhydroxyalkanoate synthase (EC 2.3.1.B3). Any D-lactate dehydrogenase enzyme, propionyl-CoA transferase enzyme and polyhydroxyalkanoate synthase enzyme, whether encoded by an endogenous or heterologous gene, can be used according to the method of this invention. In a preferred embodiment, the heterologous gene encoding the enzyme D-lactate dehydrogenase is a mutated form of *E. coli* ldhA (Gene ID: 946315 NC_000913.3). Specifically, this sequence has the following nucleotide mutations: T387C, A537G, T636C, A663T, A726G, G777A, A798G, G825A, C828T, C885T (SEQ ID NO: 1).

[0031] In another preferred embodiment, the enzyme propionyl-CoA transferase is the mutated version of the enzyme propionyl-CoA transferase (Pct) of *Clostridium propionicum*. This mutated version, called Pct540, has an amino acid substitution at position 193 in which the valine is replaced by an alanine (V193A) (Park et al., WO2009/022797; Yang et al., 2010). Preferably, the "codon usage" of the heterologous gene encoding the Pct of *Clostridium propionicum* (Gene ID: AJ276553), mutated in the Pct540 version, is optimized for translation in yeast (SEQ ID NO: 2).

[0032] In a further preferred embodiment, the enzyme polyhydroxyalkanoate synthase is the mutated version of the enzyme polyhydroxyalkanoate synthase C1 (PhaC1) of *Pseudomonas resinovorans*. This mutated version, called PhaC1437Pre, has four amino acid substitutions, in which the glutamic acid at position 130 is replaced by aspartic acid (E130D), the serine at position 325 is replaced by threonine (S325T), the serine at position 477 is replaced from glycine (S477G), glutamine at position 481 is replaced by lysine (Q481K) (Yang et al., 2011). Preferably, the "codon usage" of the heterologous gene encoding the PhaC1 of *Pseudomonas resinovorans* (Gene Accession no.: AF129396), mutated in the PhaC1437Pre version, is optimized for translation in yeast (SEQ ID NO: 3).

[0033] In another embodiment of the invention, the cell is capable of producing PLLA by expressing exogenous genes, introduced therein, coding for the enzymes involved in the polymer synthesis. The enzymes involved in the aforementioned production are: i) the enzyme L-lactate dehydrogenase (EC 1.1.1.27), ii) the enzyme propionyl-CoA transferase (EC 2.8.3.1), iii) the enzyme polyhydroxyalkanoate synthase (EC 2.3.1.B3). Any L-lactate dehydrogenase enzyme, propionyl-CoA transferase enzyme and polyhydroxyalkanoate synthase enzyme, whether encoded by an endogenous or heterologous gene, can be used according to the method of the invention. In a preferred embodiment, the heterologous gene encoding the enzyme L-lactate dehydrogenase is a mutated version of the ldh1 gene of *Lactobacillus plantarum* (Gene Accession no.: X70926). Specifically, this sequence has the following nucleotide mutations: T1A, T48C, C160G, G255T, G905C (Branduardi et al., 2006) (SEQ ID NO: 4).

[0034] In another preferred embodiment, the enzyme propionyl-CoA transferase is the mutated version of the enzyme propionyl-CoA transferase (Pct) of *Clostridium propionicum*. This mutated version, called Pct540, has an amino acid substitution at position 193 in which the valine is replaced by an alanine (V193A) (Park et al., WO2009/022797; Yang et al., 2010). Preferably the "codon usage" of the heterologous gene encoding the Pct of *Clostridium propionicum* (Gene ID: AJ276553), mutated in the Pct540 version, is optimized for translation in yeast (SEQ ID NO: 2).

[0035] In a further preferred embodiment, the enzyme polyhydroxyalkanoate synthase is the mutated version of the enzyme polyhydroxyalkanoate synthase C1 (PhaC1) of *Pseudomonas resinovorans*. This mutated version, called PhaC1437Pre, has four amino acid substitutions, in which the glutamic acid at position 130 is replaced by aspartic acid (E130D), the serine at position 325 is replaced by threonine (S325T), the serine at position 477 is replaced by glycine (S477G), glutamine at position 481 is replaced by lysine (Q481K) (Yang et al., 2011). Preferably, the "codon usage" of the heterologous gene encoding the PhaC1 of *Pseudomonas resinovorans* (Gene Accession no.: AF129396), mutated in the PhaC1437Pre version, is optimized for translation in yeast (SEQ ID NO: 3).

[0036] Surprisingly, the propionyl-CoA transferase and polyhydroxyalkanoate synthase enzymatic activities involved in PLLA production are the same as those required for PDLA synthesis. Unexpectedly, the present invention discloses that the enzymes propionyl-CoA transferase (Pct) and polyhydroxyalkanoate synthase C1 (PhaC1) can efficiently accept substrates in their enantiomeric form L. In literature there are no evidences that the enzyme propionyl-

CoA transferase (Pct) can accept “in vivo” a substrate in the enantiomeric form L. The only study reported in literature has been conducted “in vitro” by Schweiger and Buckel (1984) and it shows that, although enzyme catalysis can occur on both isoforms, the enzyme has a clear preference of substrate with respect to D-lactate compared to the corresponding L form.

[0037] Similarly, considering the polyhydroxyalkanoate synthase, in literature there are no examples of polymerization conducted by this enzyme on monomers in the enantiomeric form L, independently from the polyhydroxyalkanoate synthase considered (type I, II, III).

[0038] This is clearly documented in BRENDA, one of the main database for known enzymes (<https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B2>, <https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B3>, <https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B4>).

Consistently, the published productions of homo- and copolymer of lactate in cells refer in fact to the polymerization of lactate monomers exclusively in the D form (Dusseaux et al., WO2017/108577; Lee et al., U.S. Pat. No. 9,120,891; and Cho et al., WO2006/126796).

[0039] Therefore, it is surprising that the cell(s) of the present invention is capable of producing a polyester biopolymer consisting of lactate monomers in the enantiomeric form L. This is further surprising if we consider that no polyester biopolymer synthesized by a cell (natural or engineered for the purpose) is constituted by monomers in enantiomeric form L: a clear example are the other polymers sharing bioplastic properties like the polyhydroxyalkanoates (PHA), which possess monomeric units exclusively in the D form (Singh and Yakhmi, 2017).

[0040] Since lactic acid is a key intermediate for the production of PDLA and/or PLLA, the intracellular production of this acid from glucose and/or other sugars, by engineering the expression levels of known genes, leads to an increase in production of lactic acid and therefore of PDLA and/or PLLA. Known engineered pathways for the efficient use of glucose and/or pentose sugars (xylose, arabinose) can be exploited for the production of PDLA and/or PLLA from sugars, which derive from residual biomass and therefore they are not in competition with the agri-food chain.

[0041] Therefore, according to a further embodiment, the cell able to produce PLLA/PDLA comprises intracellular levels of sugars and/or catabolic intermediates, deriving from them, greater than a corresponding wild-type cell, by cloning at least one of genes coding for proteins responsible for the internalization and/or catabolism of sugars. According to a preferred embodiment, said sugars are selected from glucose and carbohydrates deriving from chemical and/or enzymatic hydrolysis (enzymes belonging to the superfamilies of laccases, hydrolases, cellulases and hemicellulases, see Kumar et al., 2009) of a residual biomass. Preferably, said carbohydrates are hexoses and pentoses, including glucose, mannose, galactose, xylose, arabinose, and mixtures thereof. Therefore, the polymers of interest can be produced in a process that includes the hydrolysis of residual biomasses by enzymatic and/or chemical-physical means, for example by means of steam explosion, which leads to a solution enriched in simple sugars.

[0042] In addition or alternatively, intracellular lactic acid levels can be increased by eliminating competitive pathways to its production. As an illustrative and non-limiting

example, the genes coding for pyruvate decarboxylase enzymes can be deleted (i.e. PDC1 Gene ID: 850733, Sequence NC_001144.5; PDC5 Gene ID: 850825, Sequence NC_001144.5; PDC6 Gene ID: 852978, Sequence NC_001139.9) and/or alcohol dehydrogenases, which lead to the formation of ethanol (i.e. ADHJ Gene ID: 854068, Sequence NC_001147.6).

[0043] Thus, in a further aspect the invention provides a process for the production of PLLA or PDLA that includes the following steps:

[0044] (i) culture of a cell as described herein in a culture medium comprising a carbon source;

[0045] (ii) recovery of the cell mass containing the polymer; and optionally

[0046] (iii) extraction of PLLA or PDLA from cells.

[0047] The cell used for the production of PLLA can be prokaryotic or eukaryotic. The cell used for the production of PDLA is eukaryotic. In a preferred embodiment, the eukaryotic cell is a yeast cell, more preferably a *Saccharomyces cerevisiae* cell and even more preferably a *Saccharomyces cerevisiae* cell. In a further preferred embodiment of the process for producing PDLA and/or PLLA according to the invention, aforementioned carbon source can be chosen among glucose and other sugars deriving from the hydrolysis of a residual biomass (i.e. hexose, pentose). Preferably, said sugars are hexose, preferably glucose, or pentose, preferably xylose and/or arabinose, and mixtures thereof.

[0048] In a further preferred embodiment of the PDLA and/or PLLA production process according to the invention, said carbon source can be present in an amount from 10 g/L to 1000 g/L, preferably being 20 g/L and 100 g/L.

[0049] In another preferred embodiment, the culture medium is not supplemented with lactic acid.

[0050] PDLA and/or PLLA extraction from cells can be performed using solvents.

[0051] Alternatively, the cellular biomass containing the polymer can be used directly.

BRIEF DESCRIPTION OF THE DRAWINGS

[0052] FIG. 1 shows the map of the recombinant vector pTEFLEU2-ldhA harboring the ldhA gene deriving from *E. coli*;

[0053] FIG. 2 shows the map of the recombinant vector pTEFLEU2-ldh1 harboring the ldh1 gene deriving from *L. plantarum*;

[0054] FIG. 3 shows the map of the recombinant vector pYX212-Pct540 harboring the Pct540 gene deriving from the Pct of *C. propionicum*;

[0055] FIG. 4 shows the map of the recombinant vector pYX022-PhaC1437Pre harboring the PhaC1437Pre gene deriving from the PhaC1 of *P. resinovorans*;

[0056] FIG. 5 shows the metabolic pathway for PDLA production starting from glucose via pyruvate, D-lactate and D-lactyl CoA (panel A), and the metabolic pathway for PLLA production from glucose via pyruvate, L-lactate and L-lactyl CoA (panel B);

[0057] FIG. 6 shows a representative graph of the cell growth trend over time of an engineered strain for PDLA production, of an engineered strain for PLLA production and of a control strain expressing only the ldhA and Pct540 genes, providing glucose 20 g/L as carbon source (upper panel); histograms relating to the conversion yield of glucose into ethanol and of glucose into glycerol (lower panel);

[0058] FIG. 7 shows the dot plots relating to the fluorescence emitted by cells stained with Nile red dye, for the control strain expressing *ldhA* and *Pct540* (panel A), for the engineered strain for the production of PDLA (panel B) and for the engineered strain for PLLA production (panel C). These measurements were performed at different times from the inoculum (24 hours, 48 hours, 72 hours) by flow cytometry (FACS); in the graphs, the intensity of the fluorescence emitted at 620 nm is reported on a logarithmic scale on the abscissa axis while the Forward Scatter (FS) signal, relative to the cell size, is shown on the ordinate axis. The gate, fixed for all analyzes, indicates the percentage of cells positive to Nile red staining;

[0059] FIG. 8 shows the data relating to the GC-MS analysis of pure (commercial) lactic acid subjected to methanolysis in acidic conditions. The reported chromatogram is related to the first 5 minutes of analysis. For the single peak obtained, at the retention time of 2.26 minutes, the relative mass spectrum is reported with the percentage of identification with methyl lactate.

[0060] FIG. 9 shows data relating to the GC-MS analysis of cells engineered for PDLA production, lyophilized and subjected to methanolysis in acidic conditions. The reported chromatogram is related to the first 5 minutes of analysis. For the peak at the retention time of 2.20 minutes the relative mass spectrum is reported with the percentage of identification with methyl lactate;

[0061] FIG. 10 shows the data relating to the GC-MS analysis of cells engineered for PLLA production, lyophilized and subjected to methanolysis in acidic conditions. The reported chromatogram is related to the first 5 minutes of analysis. For the peak at the retention time of 2.22 minutes the relative mass spectrum is reported with the percentage of identification with methyl lactate;

[0062] FIG. 11 shows the chromatogram relating to the first 5 minutes of GC analysis of lyophilized cells expressing *ldhA* and *Pct* and subjected to methanolysis;

[0063] FIG. 12 shows the data relating to the GC-MS analysis of samples deriving from solvent extraction of lyophilized cells engineered for PDLA production and subjected to methanolysis in acidic conditions. The reported chromatogram is related to the first 5 minutes of analysis. For the peak at the retention time of 2.24 minutes the relative mass spectrum is reported with the percentage of identification with methyl lactate.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Definitions

[0064] The term “biomass” defines any substance of organic origin that can regenerate in times compatible with its consumption, destined for the production of bioenergy and/or biofuels and/or biomaterials. This contrasts with fossil biomasses, whose regeneration times exceed their consumption by several orders of magnitude.

[0065] “Residual biomass” means the biodegradable fraction of waste and/or residues of biological origin from agriculture (including vegetable and/or animal compounds) and/or from forestry and/or related industries, including fishing and/or aquaculture, mowing and pruning from public and private green areas, as well as the biodegradable part of industrial and/or urban waste.

[0066] The “production yield” is defined as the ratio between the quantity of product obtained and the quantity of substrate consumed.

[0067] The term “vector” indicates a DNA construct comprising a DNA sequence that is linked to a control sequence capable of leading to the expression of the aforementioned DNA in a suitable host. In this invention the typical plasmid vector used has: a) or an origin of replication which allows the effective replication of the plasmid so that in each cell of the selected host there are tens of copies of the plasmid vector, or a DNA sequence which allows the integration of the plasmid vector in a chromosome of each cell of the chosen host; b) a selection marker such that a cell correctly transformed with the plasmid vector can be selected; c) a DNA sequence comprising recognition sites for restriction enzymes in order to introduce exogenous DNA into the plasmid vector by a process called ligation.

[0068] As generally reported in the state of the art, in order to express the gene inserted in the host cell, the coding sequence must be correctly and functionally related to regulatory elements of transcription, translation and expression functioning in the selected expression host.

[0069] The term “transformation” here used means that the DNA, once introduced into the cell, can replicate outside of chromosomes or as part of an entire chromosome.

EXAMPLES

Example 1: Construction of the Recombinant Vector pTEFLEU2-*ldhA* Harboring the *ldhA* Gene

[0070] The coding sequence of the *ldhA* gene was amplified by PCR using as a template the genomic DNA of *E. coli* and specific oligonucleotides (SEQ ID NO: 5; SEQ ID NO: 6). It is as follows: after 30 seconds of denaturation at 98° C., 25 cycles (denaturation of 10 seconds at 98° C., annealing of 30 seconds at 72° C. and elongation of 60 seconds at 72° C.), followed by a final elongation of 2 minutes at 72° C. The PCR product and the pTEFLEU2 target vector were digested with the *EcoRI* and *XhoI* restriction enzymes and after their ligation, the recombinant pTEFLEU2-*ldhA* vector was obtained (FIG. 1).

Example 2: Construction of the Recombinant Vector pTEFLEU2-*Ldh1* Harboring the *Ldh1* Gene

[0071] The *ldh1* gene of *L. plantarum* (SEQ ID NO: 4) was excised from the vector p022TLP (Branduardi et al., 2006) by digestion with the *EcoRI* restriction enzyme. The DNA fragment corresponding to the *ldh1* gene having *EcoRI* ends was ligated with the target vector pTEFLEU2, after its digestion with *EcoRI*, leading to the obtaining of the recombinant expression vector pTEFLEU2-*ldh1* (FIG. 2).

Example 3: Construction of the Recombinant pYX212-*Pct540* Vector Harboring the *Pct540* Gene

[0072] The coding sequence of the mutated version of the *Pct* gene of *C. propionicum*, *Pct540* (SEQ ID NO: 3), preceded by the sequence of the pTDH3 promoter of *S. cerevisiae* (SEQ ID NO: 7) have been synthesized de novo and cloned by the manufacturing company into the pEX-A2 vector (Eurofins Genomics), obtaining the pEX-A2-*Pct540* vector. In particular, the sequence of the *Pct540* gene has codon usage optimized for yeast cells. The pEX-A2-*Pct540* vector was linearized with the restriction enzyme *BglII*, and

the pTDH3-Pct540 DNA fragment was excised from the aforementioned linearized vector, by digestion with the restriction enzymes KpnI and NheI. The pTDH3-Pct540 fragment with KpnI/NheI ends was cloned in the target vector pYX212 (R&D Systems, Inc., Wiesbaden, D), digested with the restriction enzymes KpnI and NheI and therefore lacking the pTPI promoter of *S. cerevisiae*. The ligation of the two DNA fragments led to the obtaining of the recombinant expression vector pYX212-Pct540 (FIG. 3).

Example 4: Construction of the Recombinant Vector pYX022-PhaC1437Pre Harboring the PhaC1437Pre Gene

[0073] The coding sequence of the mutated version of the PhaC1 gene of *P. resinovorans*, or PhaC1437Pre (SEQ ID NO: 3), preceded by the sequence of the pADH1 promoter of *S. cerevisiae* (SEQ ID NO: 8) have been synthesized de novo and cloned by the manufacturing company into the pEX-K4 vector (Eurofins Genomics). In particular, the PhaC1437Pre gene sequence has codon usage optimized for yeast cells. The pADH1-PhaC1437Pre DNA fragment was excised by the pEX-K4 vector by digestion with the restriction enzymes AatII and NheI. The pADH1-PhaC1437Pre fragment with AatII/NheI ends was cloned in the target vector pYX022 (R&D Systems, Inc., Wiesbaden, D), digested with the restriction enzymes AatII and NheI and therefore lacking the pTPI promoter of *S. cerevisiae*. The ligation of the two DNA fragments led to the obtaining of the recombinant expression vector pYX022-PhaC1437Pre (FIG. 4).

Example 5: Construction of the Recombinant Strain of *S. cerevisiae* for the Production of PDLA

[0074] The CEN.PK laboratory strain of *S. cerevisiae* was transformed with the vectors pTEFLEU2-IhdA, pYX212-Pct540 and pYX022-PhaC1437Pre, described respectively in examples 1, 3, 4. The graphic representation of the metabolic pathway for PDLA synthesis starting from glucose via pyruvate, D-lactate and D-lactoyl-CoA, in the recombinant strain is shown in FIG. 5A.

Example 6: Construction of the Recombinant Strain of *S. cerevisiae* for the Production of PLLA

[0075] The *S. cerevisiae* CEN.PK laboratory strain was transformed with the vectors pTEFLEU2-Ihd1, pYX212-Pct540 and pYX022-PhaC1437Pre, described respectively in examples 2, 3, 4. The graphic representation of the metabolic pathway for PLLA synthesis starting from glucose via pyruvate, L-lactate and L-lactyl-CoA, in the recombinant strain is shown in FIG. 5B.

Example 7: Construction of the Recombinant Strain of *S. cerevisiae* as a Negative Control for PLA Synthesis

[0076] The *S. cerevisiae* CEN.PK laboratory strain was transformed with the pTEFLEU2-IhdA and pYX212-Pct540 vectors. The aforementioned recombinant strain lacks the polyhydroxyalkanoate synthase activity and it is therefore used in the following examples as a negative control for PDLA and PLLA production. In fact, independently of the

stereochemistry of lactate, the absence of polyhydroxyalkanoate synthase activity does not allow the polymerization of lactyl-CoA monomers.

Example 8: Cell Growth Trend and Production of the Main Extracellular Metabolites Over Time in the Engineered Strain for PDLA Production, in the Engineered Strain for PLLA Production and in the Control Strain

[0077] Cells of the CEN.PK pTEFLEU2-IhdA, pYX212-Pct540, pYX022-PhaC1437Pre strain engineered for the production of PDLA, of the CEN.PK pTEFLEU2-Ihd1, pYX212-Pct540, pYX022-PhaC1437Pre strain engineered for the production of PLLA and CEN.PK pTEFLEU2-IhdA, pYX212-Pct540 strain (used as a control) were grown in the presence of glucose 20 g/L and Yeast Nitrogen Base (YNB) 6.7 g/L. The cells were inoculated at an optical density of 0.05 (OD 660 nm) in 20 mL of medium in 100 mL flasks and incubated at 30° C. on an orbital shaker at 160 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals. The extracellular concentration of glucose, acetate, ethanol and glycerol was determined by HPLC using H₂SO₄ 5 mN as a mobile phase and a Rezex ROA H+ column (8%) 300×7.8 mm with styrene sulfonate-divinylbenzene matrix (Phenomenex).

[0078] As shown in FIG. 6 (upper panel) the CEN.PK strain engineered for PDLA production and the engineered strain for PLLA production strongly differ from the growth kinetic of the control strain. Surprisingly, these strains are characterized by a slower cell growth and by a lower cell biomass at the end of fermentation, compared to the CEN.PK pTEFLEU2-IhdA, pYX212-Pct540 strain, used as a control. Furthermore, also a comparative analysis of the growth kinetics of the strain producing PDLA or PLLA show some differences, even if less pronounced than the previous comparison. The results obtained are in accordance with the analysis of the main extracellular metabolites; the lower conversion yield of glucose into cell biomass of the engineered strains for the production of the two polymers corresponds in fact to higher conversion yields of glucose into ethanol and glycerol compared to the control strain CEN.PK pTEFLEU2-IhdA, pYX212-Pct540.

[0079] A carbon flux redirection in cells transformed with the genes encoding the enzymatic activities necessary for the production of PDLA and PLLA is demonstrated by these experiments.

Example 9: Evaluation of PDLA Production or Alternatively PLLA Production by Nile Red Staining

[0080] The cells of the CEN.PK strain engineered for PDLA production, of the engineered strain for PLLA production and of the control strain expressing only the IhdA and Pct540 genes were grown as described in Example 8. The production of PDLA or alternatively of PLLA was evaluated by staining with Nile red dye. Nile red is generally used to evaluate in live cells the accumulation of aliphatic biopolymers, such as PHA or co-polymers of D-lactic acid and other hydroxy acids, as reported in literature, by way of example, by Spiekermann et al., 1999; Glörenflo et al., 1999; Yang et al., 2010. Specifically, after 24, 48 and 72 hours from the inoculum, 0.3 OD of cells of the strains were collected and after centrifugation washed with 1 mL of phosphate buffer

(PBS; NaH_2PO_4 53 mM, Na_2HPO_4 613 mM, 75 mM NaCl). After centrifugation, they were resuspended in 1 mL of 35% (v/v) cold ethanol and incubated in ice for 20 minutes in order to permeabilize the cells to Nile red. The cells were washed again with 1 mL of PBS, and, after the addition of Nile red at the final concentration of 31.4 μM , they were incubated for 5 minutes in the dark in ice. Subsequently, the samples were analyzed by flow cytometry (FACS), using a Beckman Coulter FC-500 flow cytometer (Beckman Coulter, Fullerton, Calif., USA) equipped with an argon ion laser (excitation wavelength 488 nm, laser power 20 mW). The fluorescence emission of Nile red is acquired through a 670 nm filter (FL3 channel), in a logarithmic scale. The operating parameters were set to analyze 20 thousand cells for each sample excluding cellular debris. The data were subsequently analyzed using the Flowing software program (www.flowingsoftware.com). FIG. 7 shows the dot plots related to the fluorescence emitted, at different times from the inoculum (24, 48, 72 hours), from cells stained with Nile red. Specifically, each dot represents a single cell; its position in the graph is dependent on its fluorescence emission (reported on the x-axis) and on its dimensions (shown on the y-axis).

[0081] The dot plots show that almost all the cells engineered for the production of PDLA (panel B) and for the production of PLLA (panel C) are positive to Nile red staining. In particular, the maximum percentage of cells positive to the staining is 84% in the engineered strain for PDLA production and 97% in the PLLA-engineered strain. On the contrary, as can be observed in panel A, in the control cells expressing only the *ldhA* and *Pct540* genes, the percentage of staining positive cells is negligible and attributable to the interaction of Nile red with structural components of the cell, such as cell membranes (Mukherjee et al., 2007).

[0082] Given the direct correlation between the fluorescence emission of Nile red and the presence of aliphatic polymers, the reported data demonstrate that the metabolic engineering aimed at producing PDLA and/or PLLA (FIG. 5), object of the present invention, determine the accumulation of these polymers in eukaryotic cells.

[0083] Therefore, the synthesis of PDLA in eukaryotic cells by means of a one-step production, without the addition of lactate as substrate, without any mandatory need to attenuate or eliminate the ability to consume lactic acid as carbon source and without any mandatory need to increase the productivity of intracellular Coenzyme A (CoA) donor is described here for the first time. Furthermore, the direct synthesis of PLLA by cells is described for the first time. In literature no examples report wild-type or engineered cells capable of polymerizing hydroxy acids, and lactic acid among them, with a chiral center in L configuration. In particular, it has been described here for the first time that the enzyme polyhydroxyalkanoate synthase is able to polymerize hydroxy acid monomers with L configuration of the chiral center.

In addition, the cells of the CEN.PK strain engineered for PDLA production, of the engineered strain for PLLA production and of the control strain expressing only the *ldhA* and *Pct540* genes were grown on agar plates with molasses 20 g/L as carbon source, supplement with Nile red dye 0.5 $\mu\text{g}/\text{mL}$. After 4 days of incubation at 30° C., cell growth was observed in all the strains but only the strain engineered for PDLA production and that one engineered for PLLA production were able to accumulate intracellularly PDLA or

PLLA, respectively, they indeed resulted stained with Nile red when exposed to UV light.

Example 10: Analysis of PDLA or Alternatively of PLLA by GC-MS Analysis

[0084] In order to evaluate the composition of the polymer accumulated in the cells (example 9) a gas chromatography mass spectrometry (GC-MS) analysis was performed.

[0085] The cells of the engineered strain for PDLA production, of the engineered strain for PLLA production and of the control strain expressing only the *ldhA* and *Pct540* genes were pre-inoculated in the presence of glucose 50 g/L and YNB 6.7 g/L. The preinoculum was performed in 100 mL of medium in 500 mL flasks incubated at 30° C. on an orbital shaker at 160 rpm. After 24 hours of growth, cells were inoculated into a 2 L bioreactor at an initial OD₆₆₀ of 0.2. The operating volume of the media used in the bioreactor is 1.5 L and its composition is: glucose 50 g/L and YNB 13.4 g/L.

[0086] Growth parameters are: constant temperature of 30° C.; amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); pH maintained at 5 with additions, if necessary, of NaOH 4M and H₃PO₄ at 25% (v/v). Agitation is dependent on the percentage of oxygen dissolved in the media.

[0087] After 48 hours from the inoculum, cells were collected by centrifugation and subjected to lyophilization and then to acid methanolysis in order to break the cells and depolymerize the lactic acid polymer into methyl lactate monomer units. Methanolysis was performed according to the following protocol adapted by Brauneegg et al. (1978): the cells were dissolved in a solution of methanol acidified with sulfuric acid (3% v/v) and chloroform in a 1:1 ratio; the mixture was heated in microwave at a power of 300 W, for 200 minutes at 120° C. The solution resulting from the methanolysis of the cells was analyzed by GC-MS.

[0088] This instrument consists of a Clarus 500 gas chromatograph (PerkinElmer) and a Clarus 560 mass spectrometer (PerkinElmer). The GC is equipped with an Elite-5MS capillary column (PerkinElmer). The temperature conditions in which the gas chromatographic analysis was carried out are the following: 70° C. for 5 minutes, increase of 10° C./minute up to 150° C., increase of 20° C./minute to reach 300° C., maintained for 14.5 minutes. The sample was injected at an initial temperature of 250° C., maintained for 10 minutes.

[0089] FIG. 8 shows the chromatogram and the mass spectrum related to a pure (commercial) lactate sample esterified to methyl lactate (according to the methanolysis protocol), used as reference for the subsequent analyses performed on the engineered cells to produce PDLA or alternatively PLLA. In the chromatogram only one peak is present, with a retention time of 2.26 minutes and, by comparison with the NIST Mass Spectral Library, it shows a 97% identification rate with methyl lactate.

[0090] FIG. 9 shows the GC-MS data relating to the engineered strain for PDLA production. The peak with a retention time of 2.20 minutes corresponds to methyl lactate, with a 90.5% identification with this molecule. This result shows that lactic acid is a constituent monomer of the biopolymer accumulated by the cells. The additional peaks present in the chromatogram are traceable to molecules released by the lysis of the cellular components.

[0091] FIG. 10 shows the GC-MS data relating to the engineered strain for PLLA production. The peak with a retention time of 2.22 minutes corresponds to methyl lactate, with an 85.6% identification with this molecule. This result shows that lactic acid is a constituent monomer of the biopolymer accumulated by the cells. The additional peaks present in the chromatogram are also in this case traceable to molecules released by the lysis of the cellular components.

[0092] FIG. 11 shows data relating to the control strain, expressing only the *ldhA* and *Pct540* genes. The chromatogram shows peaks traceable to molecules released by cell lysis but not the one related to methyl lactate characterized by a retention time of about 2.2 minutes. This data therefore demonstrates that the peak relative to methyl lactate, identified in FIGS. 9 and 10, actually derives from the depolymerization of PDLA or alternatively of PLLA accumulated in specifically engineered cells, and not by free lactic acid in the cell. FIG. 12 shows the data relating to the GC-MS analysis of samples subjected to methanolysis in acidic conditions deriving from solvent extraction of lyophilized cells engineered for PDLA production. The extraction was carried out before the above-mentioned procedure of methanolysis in acid conditions, using chloroform and the Soxhlet apparatus (or extractor), as described by way of example, but not exclusive, by Yang et al. (2010), with minimal modifications. The peak with a retention time of 2.24 minutes corresponds to methyl lactate, with a 95.4% identification with this molecule. This result demonstrates that even after extraction with the Soxhlet apparatus it is possible to identify lactic acid as a constituent monomer of the biopolymer accumulated by the cells.

BIBLIOGRAPHY

- [0093] Branduardi P, Sauer M, De Gioia L, Zampella G, Valli M, Mattanovich D, Porro D. Lactate production yield from engineered yeasts is dependent from the host background, the lactate dehydrogenase source and the lactate export. *Microbial cell factories*, 2006; 5(1):4.
- [0094] Braunegg G, Sonnleitner B Y, Lafferty R M A rapid gas chromatographic method for the determination of poly- β -hydroxybutyric acid in microbial biomass. *European journal of applied microbiology and biotechnology*, 1978; 6(1):29-37.
- [0095] Castaño-Cerezo S, Pastor J M, Renilla S, Bernal V, Iborra J L, Cánvas M. An insight into the role of phosphotransacetylase (pta) and the acetate/acetyl-CoA node in *Escherichia coli*. *Microbial Cell Factories*, 2009; 8:54.
- [0096] Chen C Q and Patel M K. Plastics derived from biological sources: present and future: a technical and environmental review. *Chemical reviews*, 2011; 112(4): 2082-2099.
- [0097] Cho J H, Park S J, Lee S Y, Jung Y K. Cells or plants having a producing ability of polylactate or its copolymers and method for preparing polylactate or its copolymers using the same. WO2006/126796
- [0098] Choi M H, Ji G E, Koh K H, Ryu Y W, Park Y H. Use of waste Chinese cabbage as a substrate for yeast biomass production. *Bioresource technology*, 2002; 83(3), 251-253.
- [0099] Choi S Y, Park S J, Kim W J, Yang J E, Lee H, Shin J, Lee S Y. One-step fermentative production of poly (lactate-co-glycolate) from carbohydrates in *Escherichia coli*. *Nature biotechnology*, 2016; 34(4):435.
- [0100] Dusseaux S, Lajus S, Borsenberger V, Verbeke J, Bordes F, Marty A, Nicaud J M, Beopoulos A. WO2017/ 108577.
- [0101] Garlotta D. A literature review of poly (lactic acid). *Journal of Polymers and the Environment*, 2001; 9 (2): 63-84.
- [0102] Goldberg J S. PDLA a potential new potent topical analgesic: a case report. *Local and regional anesthesia*, 2014; 7, 59.
- [0103] Gorenflo V, Steinbüchel A, Marose S, Rieseberg M, Scheper T. Quantification of bacterial polyhydroxyalkanoic acids by Nile red staining. *Applied microbiology and biotechnology*, 1999; 51(6), 765-772.
- [0104] Jamshidian M, Tehrani E A, Imran M, Jacquot M, Desobry S. Poly-Lactic Acid: production, applications, nanocomposites, and release studies. *Comprehensive Reviews in Food Science and Food Safety*, 2010; 9(5): 552-571.
- [0105] Jansen M L, Bracher J M, Papapetridis I, Verhoeven M D, de Bruijn H, de Waal P P, van Maris A J A, Klaassen P, Pronk J T. *Saccharomyces cerevisiae* strains for second-generation ethanol production: from academic exploration to industrial implementation. *FEMS yeast research*, 2017; 17(5).
- [0106] Jung Y K, Kim T Y, Park S J, Lee S Y. Metabolic engineering of *Escherichia coli* for the production of polylactic acid and its copolymers. *Biotechnology and bioengineering*, 2010; 105(1):161-171.
- [0107] Kumar P, Barrett D M, Delwiche M J, Stroeve P. Methods for Pretreatment of Lignocellulosic Biomass for Efficient Hydrolysis and Biofuel Production. *Industrial & Engineering Chemistry Research*, 2009; 48(8):3713-3729.
- [0108] Lee S Y, Jung Y K, Yang T H, Park S J, Kim T W, U.S. Pat. No. 9,120,891.
- [0109] Li M e Borodina I. Application of synthetic biology for production of chemicals in yeast *Saccharomyces cerevisiae*. *FEMS yeast research*, 2015; 15(1), 1-12.
- [0110] Maillard D, Prud'homme R E. Differences between crystals obtained in PLLA-rich or PDLA-rich stereocomplex mixtures. *Macromolecules*, 2010; 43(9), 4006-4010.
- [0111] Marcó M B, Moineau S, Quiberoni A. Bacteriophages and dairy fermentations. *Bacteriophage*, 2012; 2(3):149-158.
- [0112] Mathuriya A S and Yakhmi J V. Polyhydroxyalkanoates: Biodegradable Plastics and Their Applications. *Handbook of Ecomaterials*, 2017; 1-29.
- [0113] Mukherjee S, Raghuraman H, Chattopadhyay A. Membrane localization and dynamics of Nile Red: effect of cholesterol. *Biochimica et Biophysica Acta (BBA)-Biomembranes*, 2007; 1768(1), 59-66.
- [0114] Okano K, Tanaka T, Ogino C, Fukuda H, Kondo A. Biotechnological production of enantiomeric pure lactic acid from renewable resources: recent achievements, perspectives, and limits. *Appl Microbiol Biotechnol.*, 2010; 85:413-423.
- [0115] Park S J, Yang T H, Kang H O, Lee S H, Lee E J, Kim T W. Mutant of propionyl-coa transferase from *Clostridium propionicum* and preparing method for PLA or PLA copolymer using the same, WO2009/022797.
- [0116] Porro D, Gasser B, Fossati T, Maurer M, Branduardi P, Sauer M, Mattanovich D. Production of recombinant proteins and metabolites in yeasts. *Applied microbiology and biotechnology*, 2011; 89(4):939-948.

- [0117] Rasal R M, Janorkar A V, Hirt D E. Poly (lactic acid) modifications. *Progress in polymer science*, 2010; 35(3):338-356.
- [0118] Schweiger G and Buckel W. On the dehydration of (R)-lactate in the fermentation of alanine to propionate by *Clostridium propionicum*. *FEBS letters*, 1984; 171(1), 79-84.
- [0119] Soares J, Demeke M M, Van de Velde M, Foulquie-Moreno M R, Kerstens D, Sels B F, Verplaetse A, Ribeiro Fernandes A A, Thevelein J M, Fernandes P M B. Fed-batch production of green coconut hydrolysates for high-gravity second-generation bioethanol fermentation with cellulolytic yeast. *Bioresource technology*, 2017; 244: 234-242.
- [0120] Spiekermann P, Rehm B H, Kalscheuer R, Baumeister D, Steinbüchel A. A sensitive, viable-colony staining method using Nile red for direct screening of bacteria that accumulate polyhydroxyalkanoic acids and other lipid storage compound figuis. *Archives of microbiology*, 1999; 171(2), 73-80.
- [0121] Tsuji H, Auras R, Lim L-T, Selke SEM. Poly (lactic acid): synthesis, structures, properties, processing, and applications. Wiley, 2011.
- [0122] Xiao L, Wang B, Yang G, Gauthier M. Poly (lactic acid)-based biomaterials: synthesis, modification and applications. In *Biomedical science, engineering and technology*. InTech, 2012.
- [0123] Yang T H, Jung Y K, Kang H O, Kim T W, Park S J, Lee S Y. Tailor-made type II *Pseudomonas* PHA synthases and their use for the biosynthesis of polylactic acid and its copolymer in recombinant *Escherichia coli*. *Applied microbiology and biotechnology*, 2011; 90(2): 603-614.
- [0124] Yang T H, Kim T W, Kang H O, Lee S H, Lee E J, Lim S C, Oh S O, Song A J, Park S J, Lee S Y. Biosynthesis of polylactic acid and its copolymers using evolved propionate CoA transferase and PHA synthase. *Biotechnology and bioengineering*, 2010; 105(1):150-160.
- [0125] SITOGRAPHY
- [0126] www.european-bioplastics.org/market/https
- [0127] <https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B2>,
- [0128] <https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B3>,
- [0129] <https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B4>,
- [0130] www.flowingsoftware.com

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1
<211> LENGTH: 990
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 1

atgaaactcg cegtttatag cacaaaacag tacgacaaga agtacctgca acaggtgaac    60
gagtcctttg gctttgagct ggaatttttt gactttctgc tgacggaaaa aaccgctaaa    120
actgccaatg gctgcgaagc ggtatgtatt ttcgtaaacg atgacggcag cgcgccggtg    180
ctggaagagc tgaaaaagca cggcggttaa tatatcgccc tgcgctgtgc cggtttcaat    240
aacgtcgacc ttgacgcggc aaaagaactg gggctgaaag tagtccgtgt tccagcctat    300
gatccagagg cegttgctga acacgccatc ggtatgatga tgacgctgaa cgcgccgtatt    360
caccgcgcgt atcagcgtac ccgtgacgct aacttctctc tggaaggctc gaccggcttt    420
actatgtatg gcaaaacggc aggcggttatc ggtaccggta aaatcgggtg ggcgatgctg    480
cgcattctga aaggttttgg tatgctctg ctggcgttcg atccgtatcc aagtgcggcg    540
gcgctggaac teggttgga gtatgtcgat ctgccaaacc tgttctctga atcagacggt    600
atctctctgc actgcccgct gacaccgaa aactaccatc tgttgaacga agccgccttc    660
gatcagatga aaaatggcgt gatgatcgtc aataccagtc gcggtgcatt gattgattct    720
caggcggcaa ttgaagcgt gaaaaatcag aaaattggtt cgttgggtat ggacgtatat    780
gagaacgaac gcgatctggt ctttgaagat aaatccaacg acgtaattca ggatgacgta    840
ttcgtcgcc tgtctgcctg ccacaacgtg ctgtttaccg ggcacacaggc attcctgaca    900
gcagaagctc tgaccagat ttctcagact acgctgcaaa acttaagcaa tctggaaaaa    960
ggcgaaacct gccccaacga actggtttta          990

```

-continued

<210> SEQ ID NO 2
 <211> LENGTH: 1575
 <212> TYPE: DNA
 <213> ORGANISM: Clostridium propionicum

<400> SEQUENCE: 2

atgagaaaag ttcgataat tactgctgac gaagctgcaa agttgatcaa agatggtgat	60
acagtaacca cttcgggttt tgcggtaat gctattcctg aggcggtaga cagagccgtt	120
gaaaagagat tcttggaaac tggcgaacct aagaatatca cctatgtcta ttgtggtagc	180
caagggaaca gagatggaag gggcgcagaa cattttgccc atgaaggact actgaaaagg	240
tatattgcag gacattgggc tacagttcca gcgctgggga aaatggctat ggaaaacaaa	300
atggaagcgt ataatgtctc tcaaggcgcc ttatgtcact tgtttaggga tatagcgagt	360
cacaaacctg gcgtctttac taaagtgggt attggcactt tcatagacc tagaaatggc	420
ggtggaaaag tgaacgatat tacgaaagaa gatattgttg agcttgttga aatcaaaggg	480
caagaatact tgttctatcc tgcctttccc atacatgttg ccttgataag aggtacatat	540
gctgatgaat cagggaaacat aactttcgag aaagaagccg ctccggttga aggaacatct	600
gtatgtcaag ctgtaaagaa tagtggaggt attgtagttg tccaggtaga aagagtggta	660
aaggcagga cattggatcc acgtcacgtt aaggttccag gaatttacgt tgattacgtt	720
gttgtggcag atcctgagga tcaccaacag tcattagatt gcgagtatga tcccgactt	780
tctggtgaac atcgtagacc agaagtgtt ggtgagccat tacctctttc cgccaagaaa	840
gtgataggca gaagaggtgc tattgagctt gagaaggacg tggctgtaaa cttaggtgta	900
ggtgctccgg aatatgtgc atcagtgcct gacgaagaag gcattgtgga ttttatgacc	960
ttaactgcag aatctggcgc tattggagge gttccagctg gtggagttag atttggtgca	1020
tcctataatg ccgatgcact aatcgatcaa ggataccagt ttgactacta tgatggtggt	1080
ggtttagact tatgctactt gggactggcc gagtgtgacg agaaaggtaa cattaatggt	1140
tcgctgtttg gtcccaggat tgcaggatgt ggaggtttca ttaatataac tcagaatacg	1200
ccaaaagtgt tcttttggc cacattcact gcaggcggtt tgaaggtaa aatcgaggac	1260
ggtaaagtca tcatcgtaca agaaggggaag caaaagaaat ttcttaagge tgtggaacag	1320
ataacattca atggcgacgt tgctttagcc aacaagcaac aagtaaccta cattacggaa	1380
agatgcgttt tcttactgaa ggaagatggt ctacatctat ccgaaattgc accaggtatt	1440
gacttgcaaa cccaaatact agatgtcatg gactttgctc caatcatcga tagagatgcg	1500
aatggtcaga tcaaactgat ggatgcccgt ttgtttgcag aagggttaat gggtttgaaa	1560
gagatgaaaa gctaa	1575

<210> SEQ ID NO 3
 <211> LENGTH: 1680
 <212> TYPE: DNA
 <213> ORGANISM: Pseudomonas resinovorans

<400> SEQUENCE: 3

atgtcaaaca agaacaacga agatttgcaa agacaagcaa gcgataaacac cctgaatttg	60
aaccagttta ttggtataag aggcaagac ctactgtcaa gcgctagaat ggtgctattg	120
caagctataa agcaaccctt tcattctgcc aaacatgttg cgcactttgg attggagtta	180
aagaatgtct tgttggggca atcgggactt caaccagaag cagatgatag aagatttaac	240

-continued

gatccagctt ggtcacaaaa tcccttgat aagcgttatc tacagacata cttggcttgg	300
agaaaaggaat tacattcttg gatagatgaa tctaacttgt ctcacaaga cgcactctaga	360
ggtcacttcc ttataaactt gatgaccgat gctatggcac ctaccaattc catggctaac	420
cctgcagccg tcaagagatt ctttgagact ggtgggaaat ccttactaga tggattaagt	480
catctggcca aagacatggt aaataatggt ggtatgcctt ctcaggtaa tatggatgca	540
tttgaagtgg gtcagaatth agcaactacc gaggagctg tagtggtcag aaacgatgtt	600
ttagagttga ttcaatacaa acccattacc gaatecagtgt atgaacgtcc gttacttgtt	660
gttccgcccc agattaacaa attttaactg ttcgacttgt cacctgaaaa gtctttagcc	720
agattttgct tgaggagtaa tctgcaaaaca ttcacgttaa gttggagaaa tcctactaag	780
gctcagagag aatggggttt aagcacgtat attgaggcac taaaggaagc aattgacgtg	840
atattgaaaa tcacgggtgc aaaagatctg aatatactag gtgcttgctt tggcggtatt	900
acgaccgtag cgttacttgg tcactatcag gctattggtg agacaaaagt caatgccttt	960
acacagatgg tcaactgtct agattttaac ttggatagtc aagtggcctt atttgetgat	1020
gaacaaactg tagaagctgc caaaaggaga tcataccaag ctggagttht ggaagggag	1080
gatatggcta aagttttcgc ttggatgagg cctaacgac tgatttggaa ttattgggtt	1140
aacaattact tacttggcaa tgaaccacca gcatttgaca tcttgattg gaataatgac	1200
actactaggt taccagcagc ctttcatggt gagttagttg agatgttcaa gactaacgct	1260
cttactagac caaatgtctt tgaagtatgt ggcactccta tagacttgaa gcaagtaaca	1320
tggattttct tttgtcttgc cgtgacaaca gaccacatta ctcttggga agcctgttat	1380
cgtagcgcac tgctacttgg aggtaaatgc gagttgtct tgtccaatgg aggccacatc	1440
aatcgatct tgaatccacc agggaatcca aaagcaagat tctccacagg atccgaaatg	1500
cctaaagacc caaaagcgtg gttagaaaac gctaccaaac atgctggattc ttggtggctg	1560
cattggcaac aatggattgg cgaagaagt ggtaaaacta agaaagcag tttcacatta	1620
ggcaataagg cctttccagc ggttgaagct tctccgggta catacttca tgaaggtaa	1680

<210> SEQ ID NO 4

<211> LENGTH: 963

<212> TYPE: DNA

<213> ORGANISM: Lactobacillus plantarum

<400> SEQUENCE: 4

atgtcaagca tgccaaatca tcaaaaagtt gtgtagtgc gcgacggcgc tgttggttct	60
agttacgctt ttgccatggc acaacaagga attgctgaag aatttgaat tgcgatggt	120
gttaaagatc ggacaaaagg tgacgacctt gatcttgaag acgccaagc attcaccgct	180
cccaagaaga tttactcagg cgaatattca gattgtaagg acgctgactt agttgttatt	240
acagccggtg cgcctcaaaa gcctggtgaa tcacgtttag acttagttaa caagaattta	300
aatatcctat catccattgt caaaccagtt gttgactccg gctttgacgg catcttctta	360
gttgctgcta accctgttga catcttaact tacgctactt ggaaattctc aggtttccca	420
aaggatcgtg tcattggttc agggacttcc ttagactctt cacgtttacg cgttgcggtta	480
ggcaacaat tcaatgttga tcctcgttcc gttgatgctt acatcatggg tgaacacggt	540
gattctgaat ttgctgctta ctcaactgca accatcggga cacgtccagt tccgatgctc	600

-continued

```

gctaaggaac aaggcgtttc tgacgaagat ttagccaagt tagaagatgg tgttcgtaac 660
aaagcttaag acatcatcaa cttgaagggt gccacgttct acggtatcgg gactgcttta 720
atgcggtatt ccaaaagccat tttacgtgat gaaaatgccg ttttaccagt aggtgcctac 780
atggacggcc aatcagcgtt aaacgacatt tatatcggga ctccggctgt gattgggtga 840
actggtttga aacaaatcat cgaatcacca ctttcagctg acgaaactcaa gaagatgcaa 900
gattccgccc caactttgaa aaaagtgtt aacgacggtt tagctgaatt agaaaataaa 960
taa 963

```

```

<210> SEQ ID NO 5
<211> LENGTH: 41
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer FW ldha

```

```
<400> SEQUENCE: 5
```

```
cttagaattc atgaaactcg ccgtttatag cacaaaacag t 41
```

```

<210> SEQ ID NO 6
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer REV ldha

```

```
<400> SEQUENCE: 6
```

```
tgtactcgag ttaaaccagt tcgttcgggc aggtttc 37
```

```

<210> SEQ ID NO 7
<211> LENGTH: 667
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

```

```
<400> SEQUENCE: 7
```

```

tcattatcaa tactgccatt tcaaagaata cgtaaataat taatagtagt gattttccta 60
actttattta gtcaaaaaat tagcctttta attctgctgt aaccocgtaca tgccaaaaat 120
agggggcggg ttacacagaa tatataacat cgtaggtgtc tgggtgaaca gtttattcct 180
ggcatccact aaatataatg gagcccgtt ttaagctgg catccagaaa aaaaaagaat 240
cccagcacca aaatattggt ttcttcacca accatcagtt cataggtcca ttctcttagc 300
gcaactacag agaacagggg cacaaaacagg caaaaaacgg gcacaacctc aatggagtga 360
tgcaacctgc ctggagtaaa tgatgacaca aggcaattga cccacgcatg tatctatctc 420
atcttcttac acctctatt acctctgct ctctctgatt tggaaaaagc tgaaaaaaa 480
ggttgaaacc agttccctga aattattccc ctacttgact aataagtata taaagacggt 540
aggtattgat tgtaattctg taaatctatt tcttaaactt cttaaattct acttttatag 600
ttagtccttt ttttagtttt aaaacaccaa gaacttagtt tcgaataaac acacataaac 660
aaacaaa 667

```

```

<210> SEQ ID NO 8
<211> LENGTH: 705
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

```

-continued

<400> SEQUENCE: 8

```

atccttttgt tgtttccggg tgtacaatat ggacttcttc ttttctggca accaaaacca    60
tacatcgggg ttcctataat accttcggtg gtctccctaa catgtaggtg gcggaggggg    120
gatatacaat agaacagata ccagacaaga cataatgggc taaacaagac tacaccaatt    180
acactgcctc attgatgggtg gtacataacg aactaatact gtagecctag acttgatagc    240
catcatcata tcgaagtttc actacccttt ttccatttgc catctattga agtaataata    300
ggcgcatgca acttcttttc ttttttttcc ttttctctct ccccgtgtg tgtctcacca    360
tatccgcaat gacaaaaaaaa tgatggaaga cactaaagga aaaaattaac gacaaagaca    420
gcaccaacag atgtcgttgt tccagagctg atgaggggta tctogaagca cagaaactt    480
tttcttctct tcattcaagc aactactctct ctaatgagca acggtatacg gccttctctc    540
cagttacttg aatttgaat aaaaaaaaag ttgctgtctt gctatcaagt ataatagac    600
ctgcaattat taatcttttg tttcctctgc attgttctcg ttccctttct tccttgtttc    660
ttttctgca caatatttca agctatacca agcatacaat caact                          705

```

1. A cell able to produce poly-D-lactic acid (PDLA) and/or poly-L-lactic acid (PLLA) through the following metabolic steps:

- (i) conversion of pyruvate into D- and/or L-lactate by means of a D- and/or L-lactate dehydrogenase enzyme;
- (ii) synthesis of D- and/or L-lactoyl-CoA by thioesterification of D- and/or L-lactate by means of an acyl-CoA transferase enzyme;
- (iii) polymerization of D- and/or L-lactoyl-CoA molecules into PDLA and/or PLLA, respectively, by means of a polyhydroxyalkanoate synthase enzyme, wherein the cell able to produce PDLA is eukaryotic and the cell able to produce PLLA is either prokaryotic or eukaryotic.

2. The cell according to claim 1, wherein the D- and/or L-lactate dehydrogenase enzyme is encoded by a heterologous gene.

3. The cell according to claim 2, wherein said heterologous gene is selected from:

- (i) gene encoding the *Escherichia coli* D-lactate dehydrogenase *ldhA* enzyme having the nucleotide sequence SEQ ID NO:1;
- (ii) gene encoding the *Lactobacillus plantarum* L-lactate dehydrogenase *ldh1* enzyme having the nucleotide sequence SEQ ID NO:4.

4. The cell according to claim 1, wherein said acyl-CoA transferase is a propionyl-CoA transferase enzyme encoded by a heterologous gene.

5. The cell according to claim 4, wherein said heterologous gene encodes a mutated form of the *Clostridium propionicum* propionyl-CoA transferase having the nucleotide sequence SEQ ID NO:2.

6. The cell according to claim 1, wherein the polyhydroxyalkanoate synthase enzyme is encoded by a heterologous gene.

7. The cell according to claim 6, wherein said heterologous gene encodes a mutated form of the *Pseudomonas*

resinovorans polyhydroxyalkanoate synthase C1 having the nucleotide sequence SEQ ID NO:3.

8. An eukaryotic cell according to claim 1, which is a fungus or yeast cell.

9. The cell according to claim 8, wherein said yeast is *Saccharomyces cerevisiae*.

10. The cell according to claim 1, further containing one or more genes responsible for sugar internalization and/or catabolism.

11. The cell according to claim 1, wherein the genes encoding the pyruvate decarboxylase and/or alcohol dehydrogenase enzymes, involved in ethanol formation, are partially or completely inactivated or deleted.

12. A method for producing poly-D-lactic acid (PDLA) and/or poly-L-lactic acid (PLLA), which comprises the following steps:

- (i) cultivating a cell according to claim 1 in a culture medium containing a carbon source;
- (ii) recovering the cell mass containing the polymer; and
- (iii) extracting PDLA and/or PLLA from the cells.

13. The method according to claim 12, wherein said carbon source is selected from: hexose and/or pentose sugar monomers; and disaccharides.

14. The method according to claim 12, wherein the culture medium is not supplemented with lactic acid.

15. A method for the preparation of poly-D-lactic acid (PDLA) and/or poly-L-lactic acid (PLLA), comprising providing the cell according to claim 1, and utilizing the cell to prepare the poly-D-lactic acid (PDLA) and/or poly-L-lactic acid (PLLA).

16. A method for producing poly-D-lactic acid (PDLA) and/or poly-L-lactic acid (PLLA), which comprises the following steps:

- (i) cultivating a cell according to claim 1 in a culture medium containing a carbon source; and
- (ii) recovering the cell mass containing the polymer.

17. The method of claim 13, wherein the hexose and/or pentose sugar monomers are selected from the group consisting of glucose, fructose, galactose, mannose, xylose, and

arabinose, and wherein the disaccharides are selected from the group consisting of lactose and saccharose.

18. The method according to claim **13**, wherein the culture medium is not supplemented with lactic acid.

19. The cell according to claim **2**, further containing one or more genes responsible for sugar internalization and/or catabolism.

20. The cell according to claim **3**, further containing one or more genes responsible for sugar internalization and/or catabolism.

* * * * *